Publication of preclinical findings for ATXA Therapeutics' NTP42
ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary arterial hypertension (PAH). These key findings show how NTP42 and antagonism of the thromboxane signalling pathway have a relevant role in alleviating the pathophysiology of PAH, representing a novel therapeutic target with marked benefits over existing standard-of-care therapies. The manuscript, entitled NTP42, a novel antagonist of the thrombo
